2019
DOI: 10.1016/j.exppara.2018.10.010
|View full text |Cite
|
Sign up to set email alerts
|

L4 stage Heligmosomoides polygyrus prevents the maturation of dendritic JAWS II cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 49 publications
0
3
0
Order By: Relevance
“…The mice were euthanized six days after infection, when the parasite was in its fourth larval stage. The larvae were collected and the sex of the L4 stage was determined as described before [ 53 ]. Two separate experiments were carried out on ES generated from nematode cultures collected from independently infected mice.…”
Section: Methodsmentioning
confidence: 99%
“…The mice were euthanized six days after infection, when the parasite was in its fourth larval stage. The larvae were collected and the sex of the L4 stage was determined as described before [ 53 ]. Two separate experiments were carried out on ES generated from nematode cultures collected from independently infected mice.…”
Section: Methodsmentioning
confidence: 99%
“…Prevention of DC maturation, upon incubation with L4 larvae of Heligmosomoides polygyrus [ 128 ] and the ability of adult stage H. polygyrus somatic antigens to inhibit proliferation and apoptosis of host immune cells [ 129 ] are other examples where parasite regulation of the NF-κB pathway is utilized by nematodes to modulate host immune responses and facilitate survival.…”
Section: Helminthsmentioning
confidence: 99%
“…Using murine cell lines is very useful due to high cell yields which facilitate experiments and allow repeated measurements. JAWS II cells are being used successfully in DC research on cancer vaccine delivery (1), anti-tumour effect (2), immunoparasitological study (3,4) and others (5)(6)(7)(8)(9)(10)(11). Immunotherapeutic vaccines show a promising weapon in the fight against cancer, especially when a personalized approach to the patient's disease is required.…”
Section: Introductionmentioning
confidence: 99%